Pars Planitis Treatment Market Outlook 2025 – In-Depth Data for Business Expansion to 2034

 Unlock 30% off global market reports with code ONLINE30 — get insights on tariff changes, macro trends, and global economic shifts.

 

 What is the current market size of the pars planitis treatment industry, and what growth rate is it expected to achieve?
 The pars planitis treatment market size has grown strongly in recent years. It will grow from $632.88 billion in 2024 to $683.54 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing awareness of autoimmune eye disorders, rising incidence of uveitis in children, growing access to ophthalmic care, expanding use of immunosuppressants, and growing patient awareness of early intervention.
 
 The pars planitis treatment market size is expected to see strong growth in the next few years. It will grow to $920.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising adoption of biologic therapies, increasing prevalence of autoimmune diseases, growing focus on pediatric eye care, expansion of health insurance coverage, and rising demand for personalized treatment. Major trends in the forecast period include shift toward steroid-sparing therapies, integration of teleophthalmology, development of long-acting implants, use of biosimilars in treatment, and rise in combination therapy.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24649&type=smp
 
 What are the major drivers contributing to the growth of the pars planitis treatment market?
 The increasing prevalence of pars planitis is expected to propel the growth of the pars planitis treatment market going forward. Pars planitis refers to an idiopathic form of intermediate uveitis that primarily causes inflammation in the vitreous and peripheral retina, typically affecting individuals aged 15 to 40. The increasing prevalence of pars planitis is due to growing awareness and improved diagnostic capabilities as advanced imaging tools enable earlier and more accurate detection. Pars planitis treatments help manage pars planitis by reducing ocular inflammation, making them essential for preserving vision and preventing complications. They enhance patient care by offering targeted therapies such as corticosteroids and immunosuppressants, improving long-term eye health and quality of life. For instance, in February 2025, according to a case report published by Mega Journal of Case Reports, a US-based medical journal, intermediate uveitis occurs at a rate of 1.4 to 2 cases per 100,000 people, with the idiopathic form, pars planitis, accounting for 70% of the cases. Therefore, the increasing prevalence of pars planitis is driving the growth of the pars planitis treatment market.
 
 What are the major market segments driving the growth of the pars planitis treatment industry?
 The pars planitis treatment market covered in this report is segmented –
 
 1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments
 2) By Diagnosis: Blood Tests, X-ray, Magnetic Resonance Imaging (MRI), Other Diagnosis
 3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
 5) By End-User: Clinic, Hospital, Other End-Users
 
 Subsegments:
 1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids
 2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
 3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery
 4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy
 5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents
 6) By Other Treatments: Antibiotics, Antivirals, Laser therapy
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report
 
 What are the key trends shaping the pars planitis treatment market in the forecast period?
 Major companies operating in the pars planitis treatment market are focusing on developing innovative solutions, such as bispecific antibodies, to enhance immune modulation, reduce ocular inflammation, and minimize systemic side effects. Bispecific antibodies are engineered proteins designed to bind to two different antigens or targets simultaneously, offering more precise and effective treatment with fewer side effects. For instance, in October 2023, Genentech Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion (RVO), in addition to age-related macular degeneration and diabetic macular edema. Vabysmo is the first bispecific antibody for ophthalmic use that targets both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), addressing inflammation and vascular leakage simultaneously. This innovative mechanism is being explored for use in intermediate uveitis, including pars planitis, where chronic inflammation in the retinal periphery requires durable and targeted intervention.
 
 Who are the key market players contributing to the growth of the pars planitis treatment industry?
 Major companies operating in the pars planitis treatment market are Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc., Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Quantum Cryogenics Ltd., Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd., Hologic Inc., Aurobindo Pharma Limited, Santen Pharmaceutical Co. Ltd., CooperSurgical Inc., AtriCure Inc., Alimera Sciences Inc., Clearside Biomedical Inc.
 
 Which regions are leading the growth of the pars planitis treatment market globally?
 North America was the largest region in the pars planitis treatment market in 2024. The regions covered in the pars planitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 How Can Companies Use The Pars Planitis Treatment Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24649
 
 Need Customized Data On Pars Planitis Treatment Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=24649&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Americas +1 310–496-7795
 Asia +44 2071930708
 Europe +44 7882 955267
 Email us at info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company